Neocarzinostatin

• Neocarzinostatin (WHO)
• ( 4S, 6R, 11R, 12R ) -11 - [( α -D-2, 6 - dideoxy -2- methylaminogalakto - pyranosyl ) oxy] -12 - {[( 2-hydroxy- 7-methoxy- methylnaphth -1 - yl ) carbonyl] oxy} -4 - [ (4R) -2-oxo -1 ,3- dioxolan-4 -yl ]-5- oxatricyclo [ 8.3.0.0 (4,6) ] tridec -9 ,13 -dien- 2,7- diyne (along with the apoprotein, IUPAC)

Cytostatic

260 ° C ( decomposition)

Soluble in water

• 0.96 mg · kg -1 ( LD50, mouse, i.v.)
• 1.7 mg · kg -1 ( LD50, mouse, ip)
• 7.2 mg · kg -1 ( LD50, mouse, s.c )
• 1.05 g · kg -1 ( LD50, mouse, oral)

Template: Infobox chemical / molecular formula search available

Zinostatin (also: neocarzinostatin ) is a drug from the group of the enediyne antibiotic with antineoplastic activity. Responsible for the anti-tumor effect is a chromophoric part which is non- covalently linked to a 113 amino acids consisting of apoprotein. The chromophore is chemically instable without binding to the peptide. The peptide consists of a single chain. Zinostatin is from cultures of Streptomyces carcinostaticus var F -41 won. The neocarzinostatin chromophore caused to DNA strand breaks, preferably on the deoxyribose of thymine.

The conjugate of Zinostatin with styrene -maleic acid copolymer was used for the treatment of hepatocellular carcinoma in Japan until 2009.